Abstract
The discovery of the clinical effectiveness of erythromycin and azithromycin in inflammatory airway diseases has inspired the discovery and development of macrolides with selective immunomodulatory activity. Erythromycin degradation continues to be a source of novel macrolides with a variety of selective biological activities. New technologies for drug discovery based in the emerging field of combinatorial biosynthesis provide the medicinal chemist with novel approaches toward the discovery of novel macrolides. Recent efforts to integrate synthetic organic medicinal chemistry with combinatorial biosynthesis have expanded the number of techniques available for macrolide synthesis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Anti-Bacterial Agents / chemistry
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Inflammatory Agents / chemistry
-
Anti-Inflammatory Agents / therapeutic use
-
Azithromycin / chemical synthesis
-
Azithromycin / therapeutic use
-
Combinatorial Chemistry Techniques
-
Cystic Fibrosis / drug therapy*
-
Cystic Fibrosis / immunology
-
Drug Design*
-
Erythromycin / analogs & derivatives*
-
Erythromycin / chemical synthesis
-
Erythromycin / therapeutic use
-
Humans
-
Immunologic Factors / chemical synthesis*
-
Immunologic Factors / therapeutic use
-
Inflammation / drug therapy
-
Inflammation / immunology
-
Macrolides / chemical synthesis*
-
Macrolides / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Anti-Inflammatory Agents
-
Immunologic Factors
-
Macrolides
-
Erythromycin
-
Azithromycin
-
picromycin